Search Videos and More

Showing 85 - 96 of 116 results

Previous| 1... 7 | 8 | 9 ...10 |Next


In Landmark Study, an Arthritis Drug Appears to Prevent Deadly Acute Graft-versus-host Disease after Bone Marrow Transplant News

In Landmark Study, an Arthritis Drug Appears to Prevent Deadly Acute Graft-versus-host Disease after Bone Marrow Transplant

An immune-suppressing drug normally used to treat rheumatoid arthritis could make bone marrow transplant safer, report researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. In a Phase 2 multi-center trial, the drug abatacept (ORENCIA®) reduced rates of severe, acute graft-versus-host disease (GVHD) and boosted rates of survival without acute GVHD or relapse in patients with leukemia and other blood cancers.
First FDA Approval of CAR T-Cell Therapy for Multiple Myeloma Marks Milestone for Patients News

First FDA Approval of CAR T-Cell Therapy for Multiple Myeloma Marks Milestone for Patients

The Food and Drug Administration (FDA) has granted its first approval of a CAR T-cell therapy for adults with multiple myeloma, bringing welcome hope for patients eligible for the treatment, according to researchers and physicians at Dana-Farber Cancer Institute.
Trial 20-153: SACI-IO for Hormone Receptor Positive Metastatic Breast Cancer Video

Trial 20-153: SACI-IO for Hormone Receptor Positive Metastatic Breast Cancer

Why test the combination of Trodelvy and pembrolizumab?
Study Underscores Need for Multidisciplinary Care for COVID-19 Long-Haulers News

Study Underscores Need for Multidisciplinary Care for COVID-19 Long-Haulers

Physicians across the country have analyzed the emerging scientific data about the long-term effects of COVID-19, creating an initial knowledge base about the clinical experiences of so-called “long-haulers” – patients with COVID-19 who experience prolonged symptoms and/or the emergence of new ones well after the initial viral infection has resolved. A comprehensive review published today in Nature Medicine offers an initial glimpse of the multi-organ effects of long-term COVID-19 and suggests a framework for the care of COVID-19 long-haulers through dedicated, multidisciplinary clinics.
New Treatments for Bladder Cancer Patients Video

New Treatments for Bladder Cancer Patients

Bladder cancer therapies, once very limited, now offer more options to treat patients than ever before. Dana-Farber Cancer Institute's Bladder Cancer Director, Guru Sonpavde, MD, details new treatments and research initiatives on the horizon for bladder cancer.
Dana-Farber Research Leads to Better Understanding of the Immune System in Kidney Cancer News

Dana-Farber Research Leads to Better Understanding of the Immune System in Kidney Cancer

In the last two decades, immunotherapy has emerged as a leading treatment for advanced renal carcinoma cancer (more commonly known as kidney cancer). This therapy is now part of the standard of care, but it doesn’t work for all patients, and almost all patients, no matter how they respond initially, become more resistant to treatment over time.
New Targeted Agent Achieves Impressive Response Rate in Trial with Patients with Uterine Serous Carcinoma News

New Targeted Agent Achieves Impressive Response Rate in Trial with Patients with Uterine Serous Carcinoma

In its first clinical trial in patients with a hard-to-treat form of uterine cancer, a targeted drug that subjects tumor cells to staggering levels of DNA damage caused tumors to shrink in nearly one-third of patients, investigators at Dana-Farber Cancer Institute reported.
Next Questions: Chronic Lymphocytic Leukemia Video

Next Questions: Chronic Lymphocytic Leukemia

Jennifer Brown, MD, PhD, shares about multiple treatments and drug therapies and how long patients can remain on them while determining the best outcomes.
Dana-Farber to Offer First CAR T-Cell Therapy for Indolent Follicular Lymphoma Following FDA Approval News

Dana-Farber to Offer First CAR T-Cell Therapy for Indolent Follicular Lymphoma Following FDA Approval

The Food and Drug Administration (FDA) approval of the first CAR T-cell therapy for indolent follicular lymphoma, a slow growing, non-Hodgkin lymphoma (NHL), represents a key advance for patients with relapsed or refractory forms of the disease. Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) will be a certified treatment center for the therapy.
Immunotherapy Combination Improves Outcomes in Advanced Kidney Cancer News

Immunotherapy Combination Improves Outcomes in Advanced Kidney Cancer

An immunotherapy agent combined with a tyrosine kinase inhibitor drug significantly improved progression-free survival and reduced the risk of death compared to a single agent treatment in advanced kidney cancer patients.
Break Through Cancer Launches Collaborative Model Across Top U.S. Research Institutions in Pursuit of Cancer Cures News

Break Through Cancer Launches Collaborative Model Across Top U.S. Research Institutions in Pursuit of Cancer Cures

Break Through Cancer today announced its formal launch as a public foundation designed to find new solutions to the most intractable challenges in cancer.
CAR T-Cell Therapy Generates Lasting Remissions in Patients with Multiple Myeloma News

CAR T-Cell Therapy Generates Lasting Remissions in Patients with Multiple Myeloma

In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international clinical trial has found.

Showing 85 - 96 of 116 results

Previous| 1... 7 | 8 | 9 ...10 |Next